News

Vertex Pharmaceuticals has moved a step closer to bringing a new treatment option to patients with immunoglobulin A nephropathy (IgAN) after the U.S. Food and Drug Administration (FDA)…
Read More...

Agios Pharmaceuticals has strengthened its position in rare hematology by securing exclusive global rights to cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK)…
Read More...

Servier has announced a major expansion of its neurology and rare disease portfolio through an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal…
Read More...

Bristol Myers Squibb has moved closer to expanding the use of its heart disease therapy Camzyos® (mavacamten) after the U.S. Food and Drug Administration (FDA) accepted a supplemental…
Read More...

Bristol Myers Squibb has received approval from the European Commission for Opdivo® (nivolumab) in combination with the chemotherapy regimen AVD (doxorubicin, vinblastine and…
Read More...

Ionis Pharmaceuticals and its partner GSK have reported positive Phase 3 results for bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B (CHB),…
Read More...

Sanofi has received a significant regulatory boost after the U.S. Food and Drug Administration (FDA) granted priority review to the new drug application (NDA) for venglustat, an…
Read More...

Innovent Biologics and Pfizer have entered into a major global oncology collaboration aimed at accelerating the development of next-generation cancer therapies, with a deal potentially…
Read More...

British pharmaceutical company GSK has reported encouraging late-stage clinical trial results for bepirovirsen, an investigational therapy for chronic hepatitis B (CHB), raising hopes…
Read More...

Novo Nordisk presented new findings from its landmark POSEIDON real-world evidence study showing that cardiovascular inflammation remains highly prevalent among people living with…
Read More...

SK bioscience has signed an agreement with Colombia’s state-owned pharmaceutical company VECOL to support vaccine technology transfer and local manufacturing, marking a significant step…
Read More...

Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. have entered into an exclusive licensing and collaboration agreement to develop and commercialize INBRIJA® (levodopa…
Read More...

Insilico Medicine and Human Life Foundation Models, Inc. (HLFM) have entered into a multi-million-dollar collaboration to develop what the companies describe as the biotechnology…
Read More...

Autobahn Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to elunetirom, the company’s lead investigational therapy for the…
Read More...

Eli Lilly and Company reported positive interim results from the Phase 1b Heart-2 clinical study of VERVE-102, an investigational gene-editing therapy designed to lower low-density…
Read More...

Pierre Fabre Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of…
Read More...

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living…
Read More...

AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of MAVIRET®…
Read More...

AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic…
Read More...

Regeneron Pharmaceuticals said the European Medicines Agency (EMA) has accepted for review under its Accelerated Assessment pathway the Marketing Authorization Application (MAA) for…
Read More...